Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders
Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders
批准号:
9519227
负责人:
Shoko Iwai
金额:
$97.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-01 至 2020-12-31
关键词:
7 year oldAddressAdultAffectAgeAlcoholismAnimal ModelAnxietyAreaAwardBackBasal GangliaBehaviorBifidobacteriumBrainCapitalCecumCell Adhesion MoleculesCentral Nervous System DiseasesChemicalsChildClinicalClinical DataClostridiumCommunicationCommunitiesComplexComputer SimulationCorpus striatum structureDNA SequenceDataData CollectionDependenceDevelopmentDiagnosisDiagnosticDiseaseDisease modelDistantDrug AddictionElementsEnvironmental Risk FactorEtiologyEvaluationExhibitsFamilyFamily StudyFecesFirst Degree RelativeFunctional disorderFundingGenesGeneticGenetic Predisposition to DiseaseGenomeGoalsGrantHeritabilityHuman MicrobiomeImmunohistochemistryIn SituIndividualInfrastructureInvestigationInvestmentsKnowledgeLightLinkLiteratureLocomotionLongitudinal cohortMeasuresMediatingMedicalMetabolic PathwayMetagenomicsMicrobeMolecularMonitorMusNational Institute of Drug AbuseNatureNeuraxisNeuronsNucleic acid sequencingOnline SystemsPathway interactionsPeptidesPerformancePharmacologic SubstancePhasePhenotypePilot ProjectsPlayPredispositionProteinsRecombinant DNAReportingRewardsRiskRisk FactorsRoleSamplingServicesShipsSiblingsSignal PathwaySmall Business Innovation Research GrantStandardizationStereotyped BehaviorSubstance AddictionSubstance Use DisorderSymptomsSynapsesSynaptic TransmissionSystemTechnologyTestingTherapeuticTimeValidationVariantaddictionautism spectrum disorderautistic childrenbaseclinically relevantcohortcommensal bacteriacostdesignexomegene productgenetic variantgenomic datagut microbiomegut microbiotahuman subjectin vivomachine learning algorithmmetabolomicsmetatranscriptomicsmicrobialmicrobial communitymicrobiomemouse modelneural circuitneural networkneuropsychiatrynovelnovel therapeutic interventionpre-clinicalpreclinical efficacypredictive modelingrecruitresearch and developmentstool sampletherapeutic developmenttherapeutic targettrait
中文摘要
尽管在诊断和治疗方面有大量持续的资金和不断出现的进步,
然而,尽管技术进步,中枢神经系统(CNS)疾病的负担仍然很大。物质使用的成本
仅疾病(SUD)估计就超过1810亿美元(2002年)。为确定风险而进行的大量工作的结果
SUD的因素和病原体表明,依赖的脆弱性是一个复杂的表型,受两者的影响,
遗传和环境因素。自闭症谱系障碍(ASD)似乎也在很大程度上受到遗传因素的影响。
和环境因素,更具体地说是肠道微生物组。
最近的研究表明,自闭症和SUD共享共同的神经网络和分子信号
途径。与ASD表型相关的几种基因产物(例如,突触细胞粘附分子
纹状体和基底神经节)影响神经元之间的突触传递,这也与成瘾有关。
奖励制度。此外,患有高功能自闭症的成年人对药物表现出更大的敏感性。
依赖我们假设,提高目前关于ASD的知识水平,特别是关于
与药物成瘾共有的属性,将激发新的治疗药物的概念化和开发。
干预措施,以纠正纹状体功能障碍的共同要素。
验证这一假设需要一个经过验证的交钥匙平台,使客户能够交付临床
来自受影响和未受影响的受试者的粪便样本,并接受由微生物组功能介导的代谢物列表
和破译CNS疾病的表型调节的临床前(体内)数据包。将对供资
通过这个奖项,我们将设计,开发和商业化一个强大的CNS微生物组相互作用(CMI)
基于平台的服务,将能够(i)阐明CNS疾病中微生物组介导的新靶点,包括
代谢物、蛋白质和肽,(ii)在标准化动物模型中收集临床前数据,
微生物生物活性分子的影响,和(iii)在广泛的治疗领域的应用,如SUD和
自闭症基于CMI平台的服务产品将允许医疗和制药客户(即,我们的目标
市场)从临床样品中快速确定诊断和治疗靶点并推断临床前疗效
估计没有风险资本或复杂基础设施的投资。
英文摘要
Despite a wealth of continued funding and ever emerging advancements in diagnostic and therapeutic
technologies, the burden of central nervous system (CNS) disorders remains substantial. The cost of Substance Use
Disorder (SUD) alone is estimated at > $181 billion (2002). The findings of numerous efforts tasked with identifying risk
factors and causative agents of SUD suggest that vulnerability to dependence is a complex phenotype influenced by both
genetics and environmental factors. Autism Spectrum Disorder (ASD) also appears to be largely impacted by both genetic
and environmental factors, more specifically the gut microbiome.
Recent studies have demonstrated that autism and SUD share common neural networks and molecular signaling
pathways. Several of the gene-products associated with the ASD phenotype (e.g., synaptic cell adhesion molecules in the
striatum and basal ganglia) affect synaptic transmission between neurons, which has also been implicated in the addiction
and reward system. In addition, adults afflicted with high functioning autism exhibit greater susceptibility to drug
dependence. We hypothesize that advancing the current state of knowledge regarding ASD, with particular regard to the
attributes shared with drug addiction, will inspire the conceptualization and development of novel therapeutic
interventions to correct common elements of striatal dysfunction.
Testing this hypothesis will require a validated turn-key platform enabling customers the ability to ship clinical
fecal samples from affected and unaffected subjects and receive a list of metabolites mediated by microbiome functions
and a pre-clinical (in vivo) data package deciphering the phenotypic modulation of the CNS disease. With the funding
received through this award, we will design, develop, and commercialize a robust CNS-microbiome-interplay (CMI)
platform-based service that will enable (i) elucidation of novel microbiome-mediated targets in CNS diseases, including
metabolites, proteins and peptides, (ii) pre-clinical data collection in standardized animal models, quantifying the
influence of microbial bioactive molecules, and (iii) application across a wide range of therapeutic areas, such as SUD and
ASD. The CMI platform-based service offering will allow medical and pharmaceutical pharma customers (i.e., our target
market) to rapidly define diagnostic and therapeutic targets from clinical samples and deduce pre-clinical efficacy
estimates sans investment in venture capital or complex infrastructure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金